UY35776A - ?antagonistas de receptor ep3 de prostaglandina?. - Google Patents

?antagonistas de receptor ep3 de prostaglandina?.

Info

Publication number
UY35776A
UY35776A UY0001035776A UY35776A UY35776A UY 35776 A UY35776 A UY 35776A UY 0001035776 A UY0001035776 A UY 0001035776A UY 35776 A UY35776 A UY 35776A UY 35776 A UY35776 A UY 35776A
Authority
UY
Uruguay
Prior art keywords
antagonistas
prostaglandina
receptor
antagonists
antagonist
Prior art date
Application number
UY0001035776A
Other languages
English (en)
Spanish (es)
Inventor
Bahnck Kevin Barry
Lee Esther Cheng Yin
Futatsugi Kentaro
Mathiowetz Alan Martin
Edmonds David James
Menhaji-Klotz Elnaz
Stanton Robert Vernon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY35776A publication Critical patent/UY35776A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001035776A 2013-10-09 2014-10-08 ?antagonistas de receptor ep3 de prostaglandina?. UY35776A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361888822P 2013-10-09 2013-10-09

Publications (1)

Publication Number Publication Date
UY35776A true UY35776A (es) 2015-05-29

Family

ID=51900918

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035776A UY35776A (es) 2013-10-09 2014-10-08 ?antagonistas de receptor ep3 de prostaglandina?.

Country Status (9)

Country Link
US (1) US9278953B2 (OSRAM)
EP (1) EP3055300B1 (OSRAM)
JP (1) JP6348582B2 (OSRAM)
AR (1) AR097963A1 (OSRAM)
CA (1) CA2926568C (OSRAM)
ES (1) ES2665153T3 (OSRAM)
TW (1) TW201527297A (OSRAM)
UY (1) UY35776A (OSRAM)
WO (1) WO2015052610A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538769A (ja) * 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
US10399944B2 (en) 2017-08-10 2019-09-03 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists
US10590083B2 (en) 2017-08-10 2020-03-17 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
US10336701B2 (en) * 2017-08-10 2019-07-02 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists
CA3100221A1 (en) 2018-05-17 2019-11-21 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP4319734A2 (en) 2021-04-07 2024-02-14 Hadasit Medical Research Services&Development Ltd. Prostaglandin receptor 3 (ep3) antagonists for use in the treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EA200300944A1 (ru) 2001-02-28 2004-04-29 Мерк Энд Ко., Инк. Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
HRP20040716A2 (en) 2002-02-27 2005-02-28 Pfizer Products Inc. Acc inhibitors
HRP20090471T1 (hr) 2004-05-12 2009-10-31 Pfizer Products Inc. Derivati prolina i njihova upotreba kao inhibitori dipeptidil-peptidaze iv
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007027630A2 (en) 2005-08-30 2007-03-08 Smithkline Beecham Corporation Genes associated with type ii diabetes mellitus
EP2463283B1 (en) 2006-04-20 2014-06-11 Pfizer Products Inc. Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
CN101541809A (zh) 2006-11-29 2009-09-23 辉瑞产品公司 螺环酮乙酰基-CoA羧化酶抑制剂
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
JP5086480B2 (ja) 2009-03-11 2012-11-28 ファイザー・インク グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof

Also Published As

Publication number Publication date
ES2665153T3 (es) 2018-04-24
TW201527297A (zh) 2015-07-16
CA2926568C (en) 2017-09-05
AR097963A1 (es) 2016-04-20
EP3055300A1 (en) 2016-08-17
US20150099782A1 (en) 2015-04-09
EP3055300B1 (en) 2018-03-07
JP6348582B2 (ja) 2018-06-27
WO2015052610A1 (en) 2015-04-16
JP2016532647A (ja) 2016-10-20
US9278953B2 (en) 2016-03-08
CA2926568A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
UY35776A (es) ?antagonistas de receptor ep3 de prostaglandina?.
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
CR20150022A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno
TWD164184S (zh) 用於建構套件之樑構件
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
PL3024468T3 (pl) Receptory limfocytów T
TWD164183S (zh) 用於建構套件之樑構件
MX2015015239A (es) Composiciones y metodos.
UY34547A (es) Un Escenario de Elevación Compuesto
KR102115217B9 (ko) 항-folr1 면역접합체 투여 레지멘
UY34682A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
DOP2016000021A (es) Imidazotiazol sulfonamidas como nematicidas
MX2015009155A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
UY4237Q (es) Taburete
UY4228Q (es) Taburete mecedor guardabultos para niños
TWD161133S (zh) 餐盤
TWD159885S (zh) 排水管用支持構件
TWD159884S (zh) 排水管用支持構件
TWD164903S (zh) 鞋子
TWD163236S (zh) 鞋
TWD163237S (zh) 鞋
TWD163602S (zh) 鞋子
TWD164964S (zh) 踏板
TH1501000059B (th) ระบบทดสอบสำหรับขบวนส่งกำลัง
TH1401005367B (th) อุปกรณ์เครื่องแยกที่มีมาตรวัดน้ำมันเชื้อเพลิง

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211215